Tumor Lysis Syndrome

10 clinical trials · Condition

Record	Firm	Date
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (NCT04745910)	M.D. Anderson Cancer Center	2022-04-05
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (NCT03605212)	Menarini Group	2017-02-27
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies (NCT01724528)	Menarini Group	2012-10-01
Elitek (Rasburicase) Immuno-Monitoring Study (NCT01097369)	Sanofi	2010-02-01
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS (NCT00360438)	M.D. Anderson Cancer Center	2006-07-01
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients (NCT00186940)	St. Jude Children's Research Hospital	2005-03-01
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome (NCT00230178)	Sanofi	2004-04-01
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy (NCT00230217)	Sanofi	2004-03-01
Fasturtec TLS Treatment / Prophylysis (NCT00651911)	Sanofi	2003-07-01

Every clearance here is in the API, with alerts when new ones post.